Is CASI Pharmaceuticals Inc (CASI) Stock About to Get Hot Friday?

The market has been high on CASI Pharmaceuticals Inc (CASI) stock recently. CASI gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

CASI Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CASI!

See Full CASI Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CASI Stock Today?

CASI Pharmaceuticals Inc (CASI) stock is trading at $3.16 as of 1:21 PM on Friday, Oct 20, a loss of -$0.44, or -12.22% from the previous closing price of $3.60. The stock has traded between $3.15 and $3.64 so far today. Volume today is 29,159 compared to average volume of 27,323.

More About CASI Pharmaceuticals Inc

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world. Click Here to get the full Stock Report for CASI Pharmaceuticals Inc stock.